Chief Executive Officer & Founder
Mr. Elam is a native of Silicon Valley who has been managing and advising healthcare and technology companies for more than 25 years.
Prior to co-founding Rezolute, Mr. Elam served in various senior leadership roles including as CEO of a European medical device company and as Head of the Pulmonary Business Unit at Nektar Therapeutics (NASDAQ: NKTR). During his tenure at Nektar, he was instrumental in reshaping the pipeline and streamlining the organization. Prior to negotiating the sale of his division to Novartis, Mr. Elam spun two entities out of Nektar, including Pearl Therapeutics which was acquired in 2013 by AstraZeneca, for $1 billion.
Earlier in his career, Mr. Elam was CFO and co-founder of a web based IT platform company serving the electronics and healthcare industries where, in addition to managing finance and business development, he established operations in the US as well as throughout Asia.
In the 1990s, Mr. Elam was a corporate partner at Wilson Sonsini Goodrich & Rosati, where he advised domestic and ex-US healthcare and technology companies on various matters from debt and equity financings to cross-border transactions. His clients included emerging growth companies as well as mature corporations such as Genentech and Hewlett Packard. Notably, he negotiated the sale of Steve Jobs' company, Next, to Apple.
In addition to serving on the board of Rezolute, he also serves on the board of directors of Savara, Inc. (NASDAQ:SVRA) in Austin Texas and Softhale in Brussels, Belgium.
Mr. Elam received his B.A. from Howard University and his J.D. from Harvard Law School.
Mr. Kim is Chairman & CEO of Handok Inc., one of the leading pharmaceutical companies in the Republic of Korea. Mr. Kim joined Handok Inc. in 1984 and spent two years between 1984 and 1986 working at Hoechst AG in Frankfurt, Germany. Between 1991 and 2005, he served as CEO of Roussel Korea, Hoechst Marion Roussel Korea and Aventis Pharma Korea and also appointed as the Country Manager of Hoechst AG and Aventis in Korea between 1996 and 2005. In 1996, he was appointed as CEO of Handok. Mr. Kim has been serving as President of Handok Jeseok Foundation since 2014. He also has been serving as President of KDG (Korean-German Society) since 2010 and Vice President of Medium Industries Committee of KCCI (The Korea Chamber of Commerce & Industry) since 2009. Mr. Kim received an MBA at the Kelley School of Business at Indiana University in 1984 and received the award of Distinguished Alumni Fellows from Indiana University. Mr. Kim completed Advanced Management Program at the Harvard Business School in 1996.
Mr. Labrucherie brings more than 20 years of senior leadership experience in finance, legal and corporate development to the Board. Prior to serving as CFO of Nektar, he was Senior Vice President, General Counsel and Secretary of Nektar from 2007 to 2016. Earlier in his career, Mr. Labrucherie was an executive at different organizations where he was responsible for global corporate alliances and mergers and acquisitions. Mr. Labrucherie began his career as an associate in the corporate practice of the law firm of Wilson Sonsini Goodrich & Rosati. Mr. Labrucherie received his J.D. from University of California Boalt Hall School of Law, where he was a member of the California Law Review and Order of the Coif, and received his B.A. from the University of California, Davis. Mr. Labrucherie is a member of the State Bar of California and is a Certified Management Accountant.
Mr. Fauchet has spent more than 35 years in the pharmaceutical industry, including most recently as the chairman of GlaxoSmithKline Japan where he joined as president & representative director in 2010. Previously, he served as senior vice president, corporate business development, head of Sanofi-Aventis Group and as a member of the Management Committee. Philippe is currently a director and senior advisor to several biotech companies, as well as a venture partner in an investment firm.